Physician

Raghavender Boothpur, MD

According to 2025 Medicare claims, Raghavender Boothpur, MD (NPI: 1578613543) practices nephrology in the Yuba City, CA market, with the plurality of this provider's patient population coming from Sutter, CA. This provider's primary affiliated billing organization is NORTH VALLEY NEPHROLOGY INC (NPI: 1861567380; TIN: 20-3587827) and primary practice location at 95991-2971.

Boothpur's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 866 traditional Medicare patients, billed 4,985 HCPCS/CPT codes, and received $348,086 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 3,033 prescription claims across 451 beneficiaries totaling $795,384 in drug costs, led by Jardiance (Empagliflozin). DME data shows 161 claims. Open Payments data shows 2 records totaling $200. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $1,024,151 to $795,384. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $408 to $124.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	832	4,478	$436,378
2016	866	4,392	$434,216
2017	830	4,002	$387,973
2018	869	3,551	$324,747
2019	866	3,811	$321,578
2020	786	3,630	$307,556
2021	815	4,126	$362,121
2022	847	3,609	$294,763
2023	870	3,627	$306,849
2024	866	4,985	$348,086

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	396	3,630	$1,024,151
2016	381	3,536	$1,110,394
2017	412	3,474	$1,069,180
2018	386	2,842	$542,600
2019	376	2,334	$347,849
2020	363	2,192	$344,525
2021	390	2,340	$533,982
2022	421	2,652	$738,532
2023	426	2,878	$804,860
2024	451	3,033	$795,384

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	297	$13,246
2016	N/R	157	$5,384
2017	N/R	69	$1,742
2018	N/R	24	$153
2019	N/R	111	$3,223
2020	N/R	176	$6,686
2021	N/R	226	$6,396
2022	N/R	170	$2,872
2023	N/R	259	$4,698
2024	N/R	161	$2,641

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	123	123	$117
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	155	262	$76
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	142	439	$61
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	515	849	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	608	1,189	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	389	17,017	$318,169
Tradjenta	Linagliptin	113	4,883	$78,174
Ozempic	Semaglutide	77	3,019	$74,772
Farxiga	Dapagliflozin Propanediol	49	3,058	$51,745
Velphoro	Sucroferric Oxyhydroxide	19	990	$49,682

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	43	$640
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	32	$565
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	49	$539
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	25	$499
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	12	$398

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$200	Aurinia Pharma U.S., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Raghavender Boothpur, MD?

Tedicare shows public-source Medicare data for Raghavender Boothpur, MD (NPI 1578613543), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Raghavender Boothpur, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Raghavender Boothpur, MD?

Raghavender Boothpur, MD is linked to NORTH VALLEY NEPHROLOGY INC (billing NPI 1861567380) in the available physician profile data.

Does Raghavender Boothpur, MD have Open Payments data?

Raghavender Boothpur, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.